Lindsay Androski - 18 Mar 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role: President and CEO, Director
Signature: /s/ David C. Hastings as attorney-in-fact for Lindsay Androski
Issuer symbol: ABUS
Transactions as of: 18 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 20 Mar 2025, 16:08:32 UTC
Previous filing: 06 Mar 2025
Next filing: 02 Feb 2026
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+310,422		$0.000000	310,422	18 Mar 2025	Common Shares	310,422	$3.20	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2	This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.

Content

Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.